Kidney Week

Abstract: TH-PO759

Outcomes after Kidney Transplantation in Anti-glomerular Basement Membrane Disease

Session Information

• Transplantation: Clinical - 1
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 2102 Transplantation: Clinical

Authors

• Brilland, Benoit, CHU Angers, Angers, France

Benoit Brilland, MD, PhD

• Traversat, Priscille, CHU Angers, Angers, France

Priscille Traversat

• Dekervel, Marine, CHU Angers, Angers, France

Marine Dekervel

• Gatault, Philippe, CHU Tours, Tours, France

Philippe Gatault

• Thierry, Antoine, Centre Hospitalier Universitaire de Poitiers, Poitiers, France

Antoine Thierry, MD, PhD

• Cornec-Le Gall, Emilie, Centre Hospitalier Regional et Universitaire de Brest, Brest, Bretagne, France

Emilie Cornec-Le Gall, MD, PhD

• Golbin, Leonard, CHU Rennes, Rennes, France

Leonard Golbin

• Duveau, Agnes, CHU Angers, Angers, France

Agnes Duveau, MD

• Piccoli, Giorgina B., Centre Hospitalier du Mans, Le Mans, Pays de la Loire, France

Giorgina B. Piccoli, MD

• Djema, Assia Ilham, Centre Hospitalier de Cholet, Cholet, France

Assia Ilham Djema, MD

• Henry, Nicolas, CH Laval, Laval, France

Nicolas Henry, MD

• Anglicheau, Dany, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France

Dany Anglicheau, MD, PhD

• Chatelet Pouliquen, Valerie, Centre Hospitalier Universitaire de Caen Normandie, Caen, Normandie, France

Valerie Chatelet Pouliquen, NP

• Caillard, Sophie, CHU Strasbourg, Strasbourg, France

Sophie Caillard, MD, PhD

• Duthe, Fabien, Centre Hospitalier Universitaire de Poitiers, Poitiers, France

Fabien Duthe, PhD

• Bertrand, Dominique, CHU Rouen, Rouen, France

Dominique Bertrand, MD

• Augusto, Jean Francois, CHU Angers, Angers, France

Jean Francois Augusto, MD, PhD

Group or Team Name

• Spiesser Group.

Background

Anti-glomerular basement membrane antibody disease-associated glomerulonephritis (GBM-GN) frequently leads to end-stage kidney disease (ESKD), requiring replacement therapy with dialysis or kidney transplant (KT). Few studies evaluated the outcome of these patients after KT. Our aim was to describe, in comparison with a control group, the occurrence of the following events: delayed graft function recovery, graft survival, relapse, acute rejection, overall survival; and to study the risk factors associated with these events.

Methods

This was a retrospective, multicenter (8 French centers), observational study including patients who received a KT between 2005 and 2023 for ESKD secondary to GBM-GN. Each vasculitis case receiving a KT was matched with 2 controls, matched on gender, center, recipient age (± 5 years) and transplant period (± 1 year). Event-free survival and the associated risk factors were analyzed.

Results

165 patients were included, including 55 with GBM-GN and 110 control patients. The median post-KT follow-up for vasculitis patients was 8.3 years. There was no difference in the occurrence of DGF between the groups (22.2 vs 18.3%, p = 0.61). In multivariable analysis, there was no difference in graft survival when comparing both groups (80% vs 81% at 10 years, p = 0.7) (Figure 1A). Only one patient experienced a relapse after KT (being anti-GBM negative at the time of transplantation). There was no difference in the incidence of acute rejection between the groups (p = 0.3). In multivariable analysis, there was no difference in overall survival when comparing both groups (87% vs 85% at 10 years, p = 0.3) (Figure 1B).

Conclusion

Kidney transplantation is a valuable option for patients with GBM-GN: outcomes are similar to those of a matched population with similar occurrence of acute rejection, graft loss or death.

Figure 1. Kidney (A) and overall (B) survival after kidney transplantation.